Cancer cells that survive radiation therapy acquire HIF-1 activity and translocate towards tumour blood vessels

Hiroshi Harada (), Masahiro Inoue, Satoshi Itasaka, Kiichi Hirota, Akiyo Morinibu, Kazumi Shinomiya, Lihua Zeng, Guangfei Ou, Yuxi Zhu, Michio Yoshimura, W. Gillies McKenna, Ruth J. Muschel and Masahiro Hiraoka
Additional contact information
Hiroshi Harada: Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Yoshida Konoe-cho
Masahiro Inoue: Osaka Medical Center for Cancer and Cardiovascular Diseases
Satoshi Itasaka: Kyoto University Graduate School of Medicine
Kiichi Hirota: Kyoto University Hospital, Kyoto University
Akiyo Morinibu: Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Yoshida Konoe-cho
Kazumi Shinomiya: Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Yoshida Konoe-cho
Lihua Zeng: Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Yoshida Konoe-cho
Guangfei Ou: Kyoto University Graduate School of Medicine
Yuxi Zhu: Group of Radiation and Tumor Biology, Career-Path Promotion Unit for Young Life Scientists, Kyoto University, Yoshida Konoe-cho
Michio Yoshimura: Kyoto University Graduate School of Medicine
W. Gillies McKenna: Gray Institute for Radiation Oncology and Biology, University of Oxford
Ruth J. Muschel: Gray Institute for Radiation Oncology and Biology, University of Oxford
Masahiro Hiraoka: Kyoto University Graduate School of Medicine

Nature Communications, 2012, vol. 3, issue 1, 1-12

Abstract: Abstract Tumour recurrence frequently occurs after radiotherapy, but the characteristics, intratumoural localization and post-irradiation behaviour of radioresistant cancer cells remain largely unknown. Here we develop a sophisticated strategy to track the post-irradiation fate of the cells, which exist in perinecrotic regions at the time of radiation. Although the perinecrotic tumour cells are originally hypoxia-inducible factor 1 (HIF-1)-negative, they acquire HIF-1 activity after surviving radiation, which triggers their translocation towards tumour blood vessels. HIF-1 inhibitors suppress the translocation and decrease the incidence of post-irradiation tumour recurrence. For the first time, our data unveil the HIF-1-dependent cellular dynamics during post-irradiation tumour recurrence and provide a rational basis for targeting HIF-1 after radiation therapy.

Date: 2012
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms1786 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:3:y:2012:i:1:d:10.1038_ncomms1786

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms1786

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().